Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.45 |
| ▸ | SPPL2A | Q8TCT8 | 4/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.45 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | PER2 | O15055 | 1/20 | 0.43 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.43 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2581278 | 0.83 | PTGES (0.47) | BACE1BCHEPER2CRY1CRY2 | |
| SCHEMBL7462782 | 0.78 | BACE1 (0.56) | BACE1NPSR1SMN1; SMN2LMNAPSEN1 | |
| SCHEMBL2575811 | 0.76 | TAS2R14 (0.49) | BACE1SPPL2AKMT2ABCHE | |
| SCHEMBL14844131 | 0.76 | BACE1 (0.45) | BACE1ALDH1A1KMT2ABCHECYP1A2 | |
| SCHEMBL6526847 | 0.75 | BACE1 (0.51) | BACE1NPSR1LMNAPSEN1PSEN2 | |
| SCHEMBL2580459 | 0.74 | BACE1 (0.47) | BACE1MEN1KMT2ABCHE | |
| SCHEMBL13673931 | 0.73 | BCHE (0.41) | BCHEHTT | |
| SCHEMBL2584515 | 0.73 | BACE1 (0.51) | BACE1NPSR1SMN1; SMN2LMNAPSEN1 | |
| SCHEMBL3968836 | 0.72 | NPSR1 (0.58) | BACE1NPSR1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL5500845 | 0.72 | MEN1 (0.57) | BACE1NPSR1SMN1; SMN2LMNAPSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43802-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-11-13 | — | — | US | claimed |
| US-RE42889-E1 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2011-11-01 | — | — | US | claimed |
| JP-3657002-B2 | — | — | 2005-06-08 | — | — | JP | claimed |
| US-20040229922-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-11-18 | — | — | US | claimed |
| US-20030191319-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2003-10-09 | — | — | US | claimed |
| US-6455581-B1 | INHIBITORS OF HIV PROTEASE. | G.D. SEARLE & CO. | 2002-09-24 | — | — | US | claimed |
| EP-0810209-B1 | Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | SEARLE & CO (US) | 2002-06-05 | — | — | EP | claimed |
| EP-0810209-A2 | Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1997-12-03 | — | — | EP | claimed |
| WO-1995006030-A1 | HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-03-02 | — | — | WO | claimed |
| WO-1994004492-A1 | HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-03-03 | — | — | WO | claimed |
| EP-0810209-B1 | Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | SEARLE & CO (US) | 2002-06-05 | — | — | EP | disclosed |
| EP-0810209-A2 | Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1997-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191319-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | BACE1 31/4885NPSR1 1934/4885SMN1; SMN2 2012/4885 |
| US-20040229922-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | BACE1 31/4885NPSR1 1934/4885SMN1; SMN2 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.